The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10739 malaria professionals are enjoying the free benefits of MalariaWorld today

artemether-lumefantrine

Monitoring of the Sensitivity In Vivo of Plasmodium falciparum to Artemether-Lumefantrine in Mali

January 31, 2021 - 15:43 -- Open Access
Author(s): 
Diarra M, Coulibaly D, Sagara I, et al.
Reference: 
Trop Med Infect Dis. 2021 Jan 24;6(1):13

In Mali, since 2007, artemether-lumefantrine has been the first choice against uncomplicated malaria. Despite its effectiveness, a rapid selection of markers of resistance to partner drugs has been documented. This work evaluated the treatment according to the World Health Organization's standard 28-day treatment method.

Anti-malarial efficacy and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows inadequate efficacy in children in Burkina Faso, 2017–2018

January 20, 2021 - 08:38 -- Open Access
Author(s): 
Adama Gansané, Leah F. Moriarty, Halidou Tinto, et al.
Reference: 
Malaria Journal 2021 20:48, 19 January 2021

The World Health Organization recommends regularly assessing the efficacy of artemisinin-based combination therapy (ACT), which is a critical tool in the fight against malaria. This study evaluated the efficacy of two artemisinin-based combinations recommended to treat uncomplicated Plasmodium falciparum malaria in Burkina Faso in three sites: Niangoloko, Nanoro, and Gourcy.

Plasmodium falciparum multidrug resistance gene-1 polymorphisms in Northern Nigeria: implications for the continued use of artemether-lumefantrine in the region

December 2, 2020 - 07:48 -- Open Access
Author(s): 
Auwal Adamu, Mahmoud Suleiman Jada, Mohammed Nasir Shuaibu, et al.
Reference: 
Malaria Journal 2020 19:439, 30 November 2020

The analysis of single nucleotide polymorphism (SNPs) in drug-resistance associated genes is a commonly used strategy for the surveillance of anti-malarial drug resistance in populations of parasites. The present study was designed and performed to provide genetic epidemiological data of the prevalence of N86Y-Y184F-D1246Y SNPs in Plasmodium falciparum multidrug resistance 1 (pfmdr1) in the malaria hotspot of Northern Nigeria.

Trends in health workers’ compliance with outpatient malaria case-management guidelines across malaria epidemiological zones in Kenya, 2010–2016

November 12, 2020 - 15:55 -- Open Access
Author(s): 
Beatrice Amboko, Kasia Stepniewska, Peter M. Macharia, Beatrice Machini, Philip Bejon, Robert W. Snow and Dejan Zurovac
Reference: 
Malaria Journal 2020 19:406, 11 November 2020

Health workers' compliance with outpatient malaria case-management guidelines has been improving, specifically regarding the universal testing of suspected cases and the use of artemisinin-based combination therapy (ACT) only for positive results (i.e., ‘test and treat’). Whether the improvements in compliance with ‘test and treat’ guidelines are consistent across different malaria endemicity areas has not been examined.

Prevalence and factors associated with carriage of Pfmdr1 polymorphisms among pregnant women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) and artemether-lumefantrine for malaria treatment in Burkina Faso

November 11, 2020 - 14:20 -- Open Access
Author(s): 
Hamtandi Magloire Natama, Rouamba Toussaint, Djamina Line Cerine Bazié, Sékou Samadoulougou, Maminata Coulibaly-Traoré, Halidou Tinto and Fati Kirakoya-Samadoulougou
Reference: 
Malaria Journal 2020 19:399, 10 November 2020

Single nucleotide polymorphisms occurring in the Plasmodium falciparum multidrug resistant gene 1 (pfmdr1) are known to be associated with aminoquinoline resistance and, therefore, represent key P. falciparum markers for monitoring resistance both in susceptible groups (children under 5 years old and pregnant women) and in the general population. This study aimed to determine prevalence and factors associated with the carriage of pfmdr1 N86Y, Y184F and D1246Y polymorphisms among pregnant women in a setting of high malaria transmission in Burkina Faso.

Continued low efficacy of artemether-lumefantrine in Angola, 2019

November 11, 2020 - 12:56 -- Open Access
Author(s): 
Dimbu PR, Horth R, Pluciński MM, et al.
Reference: 
Antimicrob Agents Chemother. 2020 Nov 9:AAC.01949-20.

Biennial therapeutic efficacy monitoring is a crucial activity for ensuring efficacy of currently used artemisinin-based combination therapy in Angola.

Not Open Access | Teratogen update: Malaria in pregnancy and the use of antimalarial drugs in the first trimester

October 21, 2020 - 09:39 -- NOT Open Access
Author(s): 
Clark RL
Reference: 
Birth Defects Res. 2020 Oct 20

Malaria is a particular problem in pregnancy because of enhanced sensitivity, the possibility of placental malaria, and adverse effects on pregnancy outcome. Artemisinin-containing combination therapies (ACTs) are the most effective antimalarials known. WHO recommends 7-day quinine therapy for uncomplicated Plasmodium falciparum malaria in the first trimester despite the superior tolerability and efficacy of 3-day ACT regimens because artemisinins caused embryolethality and/or cardiovascular malformations at relatively low doses in rats, rabbits, and monkeys.

NOT Open Access | Therapeutic Efficacy of Artemether-Lumefantrine for Uncomplicated Falciparum Malaria in Northern Zambia

October 21, 2020 - 09:31 -- NOT Open Access
Author(s): 
Ippolito MM, Pringle JC, Thuma PE, et al.
Reference: 
Am J Trop Med Hyg. 2020 Oct 19

Artemether-lumefantrine (AL) is a first-line agent for uncomplicated malaria caused by Plasmodium falciparum. The WHO recommends periodic therapeutic efficacy studies of antimalarial drugs for the detection of malaria parasite drug resistance and to inform national malaria treatment policies. We conducted a therapeutic efficacy study of AL in a high malaria transmission region of northern Zambia from December 2014 to July 2015.

NOT Open Access | HRP2/3 Mutation in Recrudescent Plasmodium falciparum Malaria Case Acquired in Ethiopia

October 21, 2020 - 08:17 -- NOT Open Access
Author(s): 
Gefen-Halevi S, Belinson V, Manor U, Gazit Z, Smollan G, Belausov N, Biber A, Schwartz E, Grossman T, Leshem E, Amit S
Reference: 
J Travel Med. 2020 Oct 15:taaa196

A 65-year-old Israeli working in Welkait, Ethiopia, not using malaria prophylaxis, developed fever. Malaria RDT was consistent with non-falciparum malaria (plasmodium LDH+/HRP-) but microscopy showed typical P. falciparum.

Efficacy of artemether-lumefantrine for treating uncomplicated Plasmodium falciparum cases and molecular surveillance of drug resistance genes in Western Myanmar

September 1, 2020 - 09:43 -- Open Access
Author(s): 
Yanrui Wu, Myat Thut Soe, Pyae Linn Aung, Luyi Zhao, Weilin Zeng, Lynette Menezes, Zhaoqing Yang, Myat Phone Kyaw and Liwang Cui
Reference: 
Malaria Journal 2020 19:304, 27 August 2020

Currently, artemisinin-based combination therapy (ACT) is the first-line anti-malarial treatment in malaria-endemic areas. However, resistance in Plasmodium falciparum to artemisinin-based combinations emerging in the Greater Mekong Sub-region is a major problem hindering malaria elimination. To continuously monitor the potential spread of ACT-resistant parasites, this study assessed the efficacy of artemether-lumefantrine (AL) for falciparum malaria in western Myanmar.

Pages

Subscribe to RSS - artemether-lumefantrine